Stifel Nicolaus Cuts Celcuity (NASDAQ:CELC) Price Target to $150.00

Celcuity (NASDAQ:CELC) had its target price decreased by Stifel Nicolaus from $175.00 to $150.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 73.21% from the stock’s current price.

A number of other equities research analysts have also recently commented on CELC. Citigroup reiterated an “outperform” rating on shares of Celcuity in a research note on Wednesday, July 15th. Guggenheim restated a “buy” rating on shares of Celcuity in a report on Wednesday, June 3rd. Weiss Ratings upgraded shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. Macquarie Infrastructure set a $160.00 target price on shares of Celcuity in a research report on Thursday, May 28th. Finally, Leerink Partners set a $155.00 price target on shares of Celcuity in a research note on Tuesday, June 2nd. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $153.64.

Celcuity Price Performance

Celcuity stock opened at $86.60 on Friday. Celcuity has a 52 week low of $44.42 and a 52 week high of $151.02. The company’s 50 day moving average price is $93.81 and its two-hundred day moving average price is $108.56. The stock has a market cap of $4.22 billion, a P/E ratio of -22.21 and a beta of 0.20. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.28). The business had revenue of $0.09 million during the quarter, compared to analyst estimates of $4.42 million. On average, equities analysts predict that Celcuity will post -3.76 earnings per share for the current year.

Institutional Investors Weigh In On Celcuity

A number of institutional investors and hedge funds have recently modified their holdings of CELC. Hsbc Holdings PLC bought a new position in shares of Celcuity in the fourth quarter valued at approximately $1,058,000. California State Teachers Retirement System lifted its stake in Celcuity by 91.2% in the 1st quarter. California State Teachers Retirement System now owns 25,580 shares of the company’s stock worth $2,920,000 after purchasing an additional 12,201 shares in the last quarter. Jennison Associates LLC bought a new position in Celcuity in the 4th quarter valued at $22,911,000. Geode Capital Management LLC boosted its holdings in Celcuity by 8.4% in the 4th quarter. Geode Capital Management LLC now owns 830,684 shares of the company’s stock valued at $82,872,000 after purchasing an additional 64,213 shares during the period. Finally, TD Asset Management Inc boosted its holdings in Celcuity by 34.0% in the 4th quarter. TD Asset Management Inc now owns 97,526 shares of the company’s stock valued at $9,727,000 after purchasing an additional 24,730 shares during the period. 63.33% of the stock is owned by hedge funds and other institutional investors.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.